CJC-1295

CJC-1295 is a synthetic 30-amino-acid analog of growth-hormone-releasing hormone (GHRH(1-29), also called sermorelin) developed by ConjuChem Inc. in the 2000s as a long-acting GH-axis research compound. Two pharmacokinetic variants are described in the literature:

• CJC-1295 with DAC (Drug Affinity Complex) · carries a maleimidopropionic-acid (MPA) linker that covalently binds plasma albumin in vivo, extending half-life to roughly one week.
• CJC-1295 No DAC (also called modified GRF(1-29) or Mod GRF 1-29) · lacks the MPA linker and has the same short half-life as native GHRH (~30 min). This is the variant typically stacked with Ipamorelin.

Peppudex card: see the mechanism + evidence-grade summary at [Peppudex / CJC-1295](https://peppudex.com/peptides/ipa-cjc1295).

Overview

The parent peptide GHRH(1-29) was identified by Roger Guillemin in 1982. The CJC-1295 modifications were designed to stabilize the molecule against dipeptidyl peptidase IV (DPP-IV) cleavage by substituting Ala²→D-Ala, Arg¹⁵→Gln, Leu²⁷→Ala, and Asp²⁸→Ser. The "No DAC" variant retains these stabilizing substitutions without the albumin-tethering linker.

Mechanism

• Binds the GHRH receptor (GHRH-R) on anterior-pituitary somatotrophs
• Triggers cAMP-mediated release of stored growth hormone
• DAC variant produces a sustained low-level GH bleed; No-DAC variant produces a pulse closer to the natural pulsatile rhythm
• When co-administered with a GHS-R agonist (ghrelin mimetic such as Ipamorelin), the dual-pathway activation amplifies the pulse synergistically

See: GHRH_receptor, Growth_hormone, Ipamorelin.

Evidence

• ConjuChem ran early-phase clinical trials in healthy adults and lipodystrophy patients in the mid-2000s with CJC-1295 with DAC. Published readouts reported sustained elevations of GH and IGF-1 following single-dose administration (Teichman et al., 2006, J Clin Endocrinol Metab).
• Two reported deaths in the lipodystrophy trial led the sponsor to halt further development of the DAC variant in humans. Subsequent investigation did not definitively establish causality, but the development program was not resumed.
• No-DAC variant (Mod GRF 1-29) has limited published clinical data; most evidence is in research animals and community-reported research protocols.

Dosing literature

Animal-model and community-reported research protocols use:

• CJC-1295 No DAC: 100–300 µg per administration, paired 1:1 by mass with Ipamorelin, 1–3 times daily, subcutaneous.
• CJC-1295 with DAC (rarely sourced today): historic research protocols used 1–2 mg per week.

No human dose is recommended by this wiki. Community ranges are reproduced for context only.

Storage

Lyophilized: 4 °C 24 months, –20 °C indefinite. Reconstituted: 2–8 °C, use within 28 days. See Reconstitution.

Regulatory status

• United States. Research use only. No FDA-approved formulation. ConjuChem clinical program halted.
• WADA. Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) in the GHRH-analog sub-category. ([2026 WADA Prohibited List](https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf))

See also

• Ipamorelin · standard No-DAC stack partner
• Growth_hormone
• Tesamorelin · FDA-approved GHRH(1-44) analog
• [Peppudex card · CJC-1295](https://peppudex.com/peptides/ipa-cjc1295) · mechanism, evidence grades A-F, FAQs, peer-reviewed sources

References

• Teichman SL, Neale A, Lawrence B, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." J Clin Endocrinol Metab. 2006;91(3):799-805.
• Sinha DK, Balasubramanian A, Tatem AJ, et al. "Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males." Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PMID 32257854.